16.08.2010 • News

Hexion Swings to Q2 Profit as Revenues Jump

Craig O. Morrison, Hexions chairman and chief executive
Craig O. Morrison, Hexion's chairman and chief executive

Privately owned Hexion Specialty Chemicals said it swung to a second-quarter profit versus a year-ago loss as sales volumes and prices rose. Net income was $52 million in the quarter versus a net loss of $56 million a year ago as revenues jumped to $1.3 billion from $956 million.

Lower expenses and an improved cost structure bolstered profit, partially offset by the impact from foreign currency, the company said. Sales volumes rose 30% from the prior-year period and 8 percent from the first quarter, aided by a recovery in Hexion's base epoxy business.

"Despite the ongoing volatility in various leading economic indicators, we remain optimistic that the recovery in volumes will continue in 2010," said Craig O. Morrison, Hexion's chairman and chief executive.

Hexion is owned by Apollo Management LP, a private equity firm that also owns the Harrah's casino chain and Norwegian Cruise Lines.

Company

Hexion Specialty Chemicals

Gennaerstr. 2-4
58642 Iserlohn
Germany

Company contact







Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read